Legg-Perthes disease and heritable thrombophilia

Journal of Pediatric Orthopaedics

Volumn 25, Issue 4, 2005, Pages 456-459

  López Franco, Mariano ^a   González Morán, Gaspar ^b   De Lucas Jr , José Carlos ^c   Llamas, Pilar ^c   Fernández De Velasco, Jaime ^c   Vivancos, José Carlos ^b   Epeldegui Torre, Tomás ^b  

^a HOSPITAL DE MÓSTOLES   (Spain)

^b HOSPITAL INFANTIL UNIVERSITARIO NIÑO JESÚS   (Spain)

^c Hospital UniversitarioFundación Jiménez Díaz   (Spain)

Author keywords

Factor V Leiden; Legg Perthes disease; Methylenetetrahydrofolate reductase C677T; Prothrombin G20210A

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); BLOOD CLOTTING FACTOR 5; PROTHROMBIN;

ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA DETERMINATION; DNA POLYMORPHISM; GENE MUTATION; HEREDITY; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; PERTHES DISEASE; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; THROMBOPHILIA; THROMBOSIS;

ADOLESCENT; ADULT; CHILD; DNA; ELECTROPHORESIS, AGAR GEL; FACTOR V; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LEGG-PERTHES DISEASE; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; MUTATION; ODDS RATIO; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PROTHROMBIN; THROMBOPHILIA;

EID: 21244500609     PISSN: 02716798     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.bpo.0000158781.29979.cf     Document Type: Article

References (35)

1. Glueck CJ, Brandt G, Gruppo R, et al. Resistance to activated protein C and Legg-Perthes disease. Clin Orthop. 1997;338:139-152.
2. Glueck CJ, Glueck HI, Welch M, et al. Familial idiopathic osteonecrosis mediated by familial hypofibrinolysis with high levels of plasminogen activator inhibitor. Thromb Haemost. 1994;71:l95-198.
3. Liu S-L, Ho T-C. The role of venous hypertension in pathogenesis of Legg-Perthes disease. A clinical and experimental study. J Bone Joint Surg [Am]. 1991;73:194-200.
4. Glueck CJ, Crawford A, Roy D, et al. Association of antithrombotic factor deficiencies and hypofibrinolysis with Legg-Perthes disease. J Bone Joint Surg [Am]. 1996;78:3-13.
5. Eldridge J, Dilley A. Austin H, et al. The role of protein C, protein S and resistance to activated protein C in Legg-Perthes disease. Pediatrics. 2001 ; 107:1329-1334.
6. García Mata S, Hidalgo Ovejero A, Martínez Grande M. Trastornos del sistema fibrinolítico y enfermedad de Legg-Calvé- Perthes. Rev Ortop Traumatol. 1999;43:119-123.
7. Glueck CJ, Glueck HI, Greenfield D, et al. Protein C and S deficiency, thrombophilia and hypofibrinolysis: pathophysiologic causes of Legg-Perthes disease. Pediatr Res. 1994;35:383-388.
8. Gruppo R, Glueck CJ, Wall E, et al. Legg-Perthes disease in three siblings, two heterozygous and one homozygous for the factor V Leiden mutation. J Pediatr. 1998;132:885-888.
9. Griffin JH, Motulsky A, Hirsch J. Diagnosis and treatment of hypercoagulable states. Hematology (Am Soc Hematol Educ Program). 1996;106-111.
10. Koster T, Rosendaal FR, de Ronde H, et al. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden thrombophilia study. Lancet. 1993;342:1503-1506.
11. Poort SR, Rosendaal FR, Reitsma PH, et al. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and increase in venous thrombosis. Blood. 1996;88:3698-3703.
12. Arruda VR, Belangero WD, Ozelo MC, et al. Inherited risk factors for thrombophilia among children with Legg-Calvé-Perthes disease. J Pediatr Orthop. 1999;19:84-87.
13. Hayek S, Kenet G, Lubetsky A, et al. Does thrombophilia play an aetiological role in Legg-Calvé-Perthes disease? J Bone Joint Surg [Br]. 1999;81:686-690.
14. Hresko MT, McDougall PA, Gorlin JB, et al. Prospective reevaluation of the association between thrombotic diathesis and Legg-Perthes disease. J Bone Joint Surg [Am]. 2002;84:1613-1618.
15. Schmitz A, Pfortner J, Protzel A, et al. Incidence of thrombophilic factor V Leiden and prothrombin G20210A mutation in Perthes disease: a pilot study. Z Orthop Ihre Grenzegeb. 2001;139:143-146.
16. Thomas DP, Morgan G, Tayton K. Perthes' disease and the relevance of thrombophila. J Bone Joint Surg [Br]. 1999;81:691-695.
17. Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994;369:64-67.
18. Kluijtmans LA, Van Den Heuvel LP, Boers GH, et al. Molecular genetic analysis in mild hyperhomocystinemia: a common mutation in the methyl-entetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet. 1996;58:35-41.
19. Gregosiewicz A, Okonski M, Stolecka D, et al. Ischemia of the femoral head in Perthes' disease: is the cause intra- or extravascular? J Pediatr Orthop. 1989;9:160-162.
20. Junker R, Koch HG, Auberger K, et al. Prothrombin G20210A gene mutation and further prothrombotic risk factors in childhood thrombophilia. Arterioscler Thromb Vasc Biol. 1999;19:2568-2572.
21. Novak Gottl U, Kopch HG, Aschkal B. Resistance to active protein C in children with venous or arterial thromboembolism. Br J Haematol. 1996; 92:992-997.
22. Schobbes R, Junker R, Auberger K, et al. Factor V G1691A and prothrombin G20210A in childhood spontaneous venous thrombosis: evidence of an age-dependent thrombotic onset in carriers of factor V G1691A and prothrombin G20210A mutation. Eur J Pediatr. 1999; 158(suppl 3):105-108.
23. Llamas Sillero P, Fernández de Velasco J, Loscertales J, et al. ProC Global: an automated screening test for factor V Leiden and prothrombin mutation 20210 G to A detection. Thromb Res. 2001;101:215-216.
24. Álvarez A, Barroso A, Robledo M, et al. Prevalencia del factor V Leiden y de la mutación G20210A del gen de la protrombina en un grupo no seleccionado de pacientes con episodios tromboticos. Sangre (Barc). 1999;44:7-12.
25. Falcon CR, Cattaneo M, Panzeri D, et al. High prevalence of hyperhomocystinemia in patients with juvenile venous thrombosis. Arterioscler Thromb. 1994;58:1080-1083.
26. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in metilentetrahydrofolate reductase. Nat Genet. 1995;10:111-113.
27. Brattstrom L, Wilcken DEL, Ohrvik J, et al. Common methylentetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease. Circulation. 1998;98:2520-2526.
28. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. Br Med J. 2002;325:1202-1206.
29. Hall DJ. Genetic aspects of Perthes' disease. A critical review. Clin Orthop. 1986;209:100-114.
30. De Stefano V, Martinelli I, Mannucci PM, et al. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. N Engl J Med. 1999;341:801-806.
31. Rosendaal FR, Koster T, Vandenbroucke JP, et al. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood. 1995;85:1504-1508.
32. Gallistl S, Reitinger T, Linhart W, et al. The role of inherited thrombotic disorders in the etiology of Legg-Perthes disease. J Pediatr Orthop. 1999; 19:82-83.
33. Sirvent N, Fisher F, el Hayek T, et al. Absence of congenital prethrombotic disorders in children with Legg-Perthes disease. J Pediatr Orthop. 2000; 9B:24-27.
34. Selligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis. N Engl J Med. 2001;344:1222-1231.
35. Catterall A. The natural history of Perthes' disease. J Bone Joint Surg [Br]. 1971;53:37-53.